161 related articles for article (PubMed ID: 21135877)
1. Prostate cancer: Reducing fracture risk in men on androgen deprivation therapy.
Shahinian VB
Nat Rev Urol; 2011 Jan; 8(1):9-10. PubMed ID: 21135877
[No Abstract] [Full Text] [Related]
2. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.
Smith MR; Morton RA; Barnette KG; Sieber PR; Malkowicz SB; Rodriguez D; Hancock ML; Steiner MS
J Urol; 2010 Oct; 184(4):1316-21. PubMed ID: 20723926
[TBL] [Abstract][Full Text] [Related]
3. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.
Smith MR; Morton RA; Barnette KG; Sieber PR; Malkowicz SB; Rodriguez D; Hancock ML; Steiner MS
J Urol; 2013 Jan; 189(1 Suppl):S45-50. PubMed ID: 23234631
[TBL] [Abstract][Full Text] [Related]
4. Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy.
Taneja SS; Smith MR; Dalton JT; Raghow S; Barnette G; Steiner M; Veverka KA
Expert Opin Investig Drugs; 2006 Mar; 15(3):293-305. PubMed ID: 16503765
[TBL] [Abstract][Full Text] [Related]
5. [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].
Kudlacek S; Puntus T
Wien Med Wochenschr; 2012 Sep; 162(17-18):380-5. PubMed ID: 22875632
[TBL] [Abstract][Full Text] [Related]
6. Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer.
Smith MR; Malkowicz SB; Brawer MK; Hancock ML; Morton RA; Steiner MS
J Urol; 2011 Dec; 186(6):2239-44. PubMed ID: 22014807
[TBL] [Abstract][Full Text] [Related]
7. Re: Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. M. R. Smith, R. A. Morton, K. G. Barnette, P. R. Sieber, S. B. Malkowicz, D. Rodriguez, M. L. Hancock and M. S. Steiner. J Urol 2010;184:1316-1321.
Langley RE; Cafferty FH; Pollock PA; Price P; Abel PD
J Urol; 2011 Jun; 185(6):2430-1; author reply 2431-2. PubMed ID: 21513954
[No Abstract] [Full Text] [Related]
8. Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer.
Morgans AK; Hancock ML; Barnette KG; Steiner MS; Morton RA; Smith MR
J Urol; 2012 Mar; 187(3):889-93. PubMed ID: 22245322
[TBL] [Abstract][Full Text] [Related]
9. Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management.
Kim HS; Freedland SJ
Curr Opin Support Palliat Care; 2010 Sep; 4(3):147-52. PubMed ID: 20592607
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer.
Saylor PJ; Morton RA; Hancock ML; Barnette KG; Steiner MS; Smith MR
J Urol; 2011 Aug; 186(2):482-6. PubMed ID: 21679977
[TBL] [Abstract][Full Text] [Related]
11. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study.
Smith MR; Malkowicz SB; Chu F; Forrest J; Sieber P; Barnette KG; Rodriquez D; Steiner MS
J Clin Oncol; 2008 Apr; 26(11):1824-9. PubMed ID: 18398147
[TBL] [Abstract][Full Text] [Related]
12. Toremifene might improve side effects of ADT.
Nierengarten MB
Lancet Oncol; 2007 Apr; 8(4):287. PubMed ID: 17436422
[No Abstract] [Full Text] [Related]
13. Bisphosphonate prescriptions in men with androgen deprivation therapy use.
Gulamhusein H; Yun L; Cheung AM; Sutradhar R; Paszat L; Warde P; Alibhai SM
JAMA; 2014 Dec; 312(21):2285-6. PubMed ID: 25462000
[No Abstract] [Full Text] [Related]
14. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
Smith MR
Oncology (Williston Park); 2004 May; 18(5 Suppl 3):21-5. PubMed ID: 15202584
[TBL] [Abstract][Full Text] [Related]
15. Fracture risk in patients with prostate cancer on androgen deprivation therapy.
López AM; Pena MA; Hernández R; Val F; Martín B; Riancho JA
Osteoporos Int; 2005 Jun; 16(6):707-11. PubMed ID: 15714259
[TBL] [Abstract][Full Text] [Related]
16. Management of osteoporosis in men on androgen deprivation therapy.
Adler RA
Maturitas; 2011 Feb; 68(2):143-7. PubMed ID: 21129866
[TBL] [Abstract][Full Text] [Related]
17. [Fracture prevention in metastatic prostate cancer].
Schweitzer D; van Melick HHE
Ned Tijdschr Geneeskd; 2020 Feb; 164():. PubMed ID: 32186812
[TBL] [Abstract][Full Text] [Related]
18. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men.
Alibhai SM; Duong-Hua M; Cheung AM; Sutradhar R; Warde P; Fleshner NE; Paszat L
J Urol; 2010 Sep; 184(3):918-23. PubMed ID: 20643458
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic evaluation of toremifene and its clinical implications for the treatment of osteoporosis.
Gennari L; Merlotti D; Stolakis K; Nuti R
Expert Opin Drug Metab Toxicol; 2012 Apr; 8(4):505-13. PubMed ID: 22356442
[TBL] [Abstract][Full Text] [Related]
20. Re: prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene.
Taneja SS
J Urol; 2013 Aug; 190(2):536. PubMed ID: 23845334
[No Abstract] [Full Text] [Related]
[Next] [New Search]
